3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Genitourinary
2
Sarcoma
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
8
Uveal Melanoma
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Lung Neoplasms
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
22
Nivolumab
17
Magnetic Resonance Spectroscopy
12
Specimen Handling
10
Cyclophosphamide
9
Radiosurgery
7
Drug Therapy
6
Radiotherapy
5
Paclitaxel
5
Ipilimumab
5
fludarabine
4
Biopsy
4
trametinib
3
sargramostim
3
Trastuzumab
3
Taxes
3
Pemetrexed
3
Metformin
3
Interleukin-2
3
Immunoglobulin G
3
Gemcitabine
3
Carboplatin
3
Bevacizumab
3
tremelimumab
2
temsirolimus
2
poly ICLC
2
pertuzumab
2
osimertinib
2
motexafin gadolinium
2
epacadostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Colony-Stimulating Factors
×
Dermatologic
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled